The American Psychiatric Association Issued a position statement 

In July 2022 The American Psychiatric Association issued a position statement stating that a growing interest involving Psychedelics for treatment of serious conditions such as treatment resisted depression and PTSD were still investigational. They are waiting on the full review of these agents for clinical indications and state that their position is that they do not support the use until they have further evidence. It is important to note both MDMA and Psilocybin containing mushrooms were both granted breakthrough Therapy Designation for the treatment of PTSD and Treatment resistant Depression and our currently in phase 3 testing at MAPS and Compass Pathways. 

We are certainly aware we are in liminal times in all aspects of life and especially in health care.  The desperate need for efficacious results for medicine use has led to states of emergency, such as the emergency use (EUA) of countermeasures during public measures in a pandemic. Although we are not advocating for EUA use of these substances, and we certainly aren’t stating this is a panacea or that there is a panacea…..we do take serious consideration of the severity of mental health issues and Substance abuse disorders that have plagued New Mexicans with severe consequences affecting the SDOH (Social Detirminates of Health) of New Mexicans for decades. We are very serious about the progress and support in the continued research as well as respect in doing so for New Mexicans. 

We want to make clear that NMPSS is a Science society and research and phase testing are critically important for our mission in creating equitable access to New Mexicans.  We also want to make clear that as New Mexicans we are serious about the continued process in developing safe, respectful, equitable measures of study and implication of policy that addresses and protects are unique cultures of New Mexico in this approach.